CA1062265A - Process of preparation of new benzylamines - Google Patents

Process of preparation of new benzylamines

Info

Publication number
CA1062265A
CA1062265A CA229,350A CA229350A CA1062265A CA 1062265 A CA1062265 A CA 1062265A CA 229350 A CA229350 A CA 229350A CA 1062265 A CA1062265 A CA 1062265A
Authority
CA
Canada
Prior art keywords
general formula
cyclopropyl
optically active
racemic
trifluoromethylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA229,350A
Other languages
French (fr)
Inventor
Jean-Claude Poignant
Pierre Roger
Charles Malen
Michel Laubie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Science Union et Cie
Original Assignee
Science Union et Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Science Union et Cie filed Critical Science Union et Cie
Priority to CA332,309A priority Critical patent/CA1078869A/en
Application granted granted Critical
Publication of CA1062265A publication Critical patent/CA1062265A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40Halogenated unsaturated alcohols
    • C07C33/50Halogenated unsaturated alcohols containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte à l'obtention de trifluorométhylbenzylamines substituées à l'azote, répondant à la formule générale I: (I) dans laquelle X est de l'hydrogène, un atome d'halogène ou un radical trifluorométhyle et les substituants R1, R2, R3 et R4 sont soit de l'hydrogène soit un substituant hydrocarboné linéaire ou cyclique, sous forme racémique ou optiquement active ainsi que des sels de ces composés avec un acide minéral ou organique qui consiste à cycliser par chauffage une .beta.-halo-éthylurée de formule générale: Les composés de formule générale I et leurs sels manifestent des propriétés pharmacologiques interessantes. En particulier ils possèdent des propriétés anti-hypertensives très marquées. Par contre ils ne manifestent de propriétés neurodépressives qu'à des doses très élevées, bien supérieures à celles utilisées pour l'effet anti-hypertensif. Les composés de formule générale I ainsi que leurs sels trouvent un emploi en thérapeutique humaine ou animale, notamment comme agent anti-hypertensif.The invention relates to the production of nitrogen-substituted trifluoromethylbenzylamines, corresponding to the general formula I: (I) in which X is hydrogen, a halogen atom or a trifluoromethyl radical and the substituents R1, R2, R3 and R4 are either hydrogen or a linear or cyclic hydrocarbon substituent, in racemic or optically active form as well as salts of these compounds with a mineral or organic acid which consists in cyclizing by heating a .beta.-halo -ethylurea of general formula: The compounds of general formula I and their salts show interesting pharmacological properties. In particular, they have very marked anti-hypertensive properties. On the other hand, they manifest neurodepressive properties only at very high doses, much higher than those used for the anti-hypertensive effect. The compounds of general formula I and their salts find use in human or animal therapy, in particular as an anti-hypertensive agent.

Description

~O~;ZZ65 La presente invention concerne de nouvelles benzyl-amines substituees a l'azote. Elle cor.cerne plus particuliere-ment des benzylamines N-substituees dont le noyau aromatique porte un substituant trifluoromethyle en position meta.
L'invention comprend specifiquement un procede d'obtention des composes de formule generale I:
X

~f - NH ~/ ¦ (I) dans laquelle X represente de l'hydrogene, un atome d'halogene ou un radical trifluoromethyle;
Rl represente un radical alcoyle inferieur ou un radical cycloalcoyle inferieur;
R2 represente de l'hydrogene ou un radical alcoyle inferieur;
R3 et R4, distinctement ou simultanement representent de l'hydrogene ou un radical alcoyle inferieur ou forment ensemble une cha~ne alcoylene ayant de 3 a 6 atomes de carbone ainsi que des sels des composes de formule generale I
avec un acide mineral ou organique, de preference un acide therapeutiquement compatible, qui consiste a cycliser par chauffage un compose de formule g~nerale II:

~1 - NH - 1l - NH - fH - fH - Hal (Il) dans laquelle la definition des substituants X, Rl, R2, R3 et R4 demeure inchangee B represente de l'oxygene `~ 106ZZ65 et Hal repr~sente un atome d'halogane pour obtenir un compose de formule generale I:

F ~ Fz R4 que l'on peut, si desire, salifier par addition d'un acide mineral ou organique ou dedoubler en ses isomeres optiques par combinaison avec un reactif optiquement actif.
L'invention comprend aussi un procede d'obtention des composes de formule generale II qui consiste en ce qu'on condense une m. trifluoromethylbenzylamine de formule generale 10 III:
X

~ C--N H 2 ( I I I ) dans laquelle X, Rl et R2 sont definis comme precedemment avec un isocyanate d'~-halogenoalcoyle de formule generale IV:
X - CH - CH - N = C = B

dans laquelle X est un atome d'halogane R3 et R4 sont definis comme precedemment et B est un atome d'oxygane pour produire une uree de formule gen~rale II.
Les composes de formule generale II peuvent egalement être obtenus par un procede qui consiste en ce que l'on condense une m. trifluoromethylbenzylamine de formule generale III avec un haloformiate d'aryle de formule generale V:

Ar ~ ~ 6 - Hal (V) o dans laquelle Ar est un radical phenyle ou un radical phenyle substitue par un ou plusieurs radicaux a caractere electrophile, pour obtenir un carbamate de formule genérale VI:
X

~f - N~ - ICl - OAr (VI) dans laquelle X, Rl, R2 et Ar sont definis comme precedemment que l'on condense avec un aminoalcanol de formule generale VII:
2HN - CH - fH - OH (VII) dans laquelle R3 et R4 sont definis comme precedemment pour obtenir une ~-hydroxy alcoyluree de formule generale VIII:
X

~f - NH - CO - NH - fH - fH - OH (VIII) et soumet celle-ci a l'action d'un agent d'haloge-nation pour former un compose de formule generale II.
Conformement au procede de l'invention, l'invention peut encore se definir par les modes d'execution suivants:
- la cyclisation du compose de formule generale Il est effectuee par chauffage de preference en milieu aqueux, en -presence ou en l'absence d'un agent basique capable de fixer la molecule d'hydracide formee lors de la reaction de cycli-sation.
- l'agent basique peut être un agent mineral comme par exemple un carbonate de metal alcalin ou alcalino-terreux, un blcarbonate alcalin, un hydroxyde de métal alcalin, un oxyde de metal alcalino-terreux, de magnesium ou d'aluminium, wn carbonate ou un phosphate de magnesium, un sel basique d'aluminium.
- l'agent basique peut être un agent organique comme par exemple une dialcoylamine, une trialcoylamine, la dimethyl-aniline, une base pyridique.
- la cyclisation s'effectue par chauffage a une temperature comprise entre 50 et 120C, selon la nature du solvant et de la nature de la molecule a deshydrogener. La cyclisation s'effectue de preference aux environs de 100.
- l'halogenoformate d'aryle de formule generale V
est de preference un chlorure ou un bromure.
- le radical aryle est de preference un radical phenyle, dinitrophenyle, nitrophenyle, ou chloro nitrophenyle.
- la condensation de l'halogenoformate d'aryle avec la m. trifluoromethyl benzylamine de formule generale III est effectuee en presence d'un agent basique comme une trialcoyl-amine, une dialcoylaniline, la pyridine, la collidine, la 4-dimethylaminopyridine ou le dimethylformamide.
- l'agent d'halogenation est par exemple le chlorure de thionyle, le pentachlorure ou le pentabromure de phosphore, l'oxychlorure de phosphore, la N-bromoacetamide.
- le dedoublement des composes de formule gen~rale I
est effectuee de preference par salification avec un acide optiquement actif comme par exemple l'acide d-tartrique, l'acide NN dimethyl tartramique, l'acide abietique, l'acide d-ou l-chrysanthemique, l'acide d-glucose l-phosphorique, l'acide l-menthoxy acetique ou l'acide d-dibenzoyl tartrique.
Le dedoublement peut être ~galement effectuê sur une matiere premiere comme par exemple une m. trifluoromethyl-benzylamine de formule generale III ou une ~-hydroxy alcoyluree de formule generale VIII.
L'invention comprend egalement l'obtention des formes optiquement actives des composes de formule generale I.
L'atome de carbone benzylique est substitue par au moins trois radicaux differents et de ce fait asymetrique. Une telle molecule peut être dedoublee en ses antipodes optiques.
En outre lorsque le cycle oxazolique est substitue par une ou plusieurs chafnes carbonees lineaires ou cycliques, les nouveaux centres de symetrie peuvent donner naissance a des composes dedoubles. Les isomeres optiques qui en resultent font egalement partie de l'invention.
L'invention a egalement pour objet un procede de preparation de la DL N- ~ a-cyclopropyl) (3-trifluoromethyl-phenyl) methy ~ 2-aminooxazoline qui consiste en ce que l'on condense la DL (3-trifluoromethylphenyl) cyclopropylmethylamine avec l'isocyanate de ~-chloroethyle pour former la N-(~-chloro-ethyl) N'- ~ cyclopropyl) (3-trifluoromathylphenyl) methy ~ uree que l'on cyclise par chauffage en milieu aqueux pour obtenir l'oxazoline desiree.
L'invention a aussi pour objet un procede de prepa-ration du 2-(a-cyclopropyl) 2-(3'-trifluoromethylphenyl) 2-(oxazolinyl-2' amino) ethane racemique-ou optiquement actif qui consiste en ce que l'on condense la 2-(3'-trifluorom~thyl-phenyl) 2-(a-cyclopropyl~ ethylamine racemique ou optiquement active avec l'isocyanate de ~-chloroethyle pour obtenir la ~-chloroethyl uree correspondante que l'on cyclise par chauffageen 2-(~-cyclopropyl) 2-(3'-trifluoromethylphenyl) 2-(oxazolinyl-
~ O ~; ZZ65 The present invention relates to new benzyl-nitrogen-substituted amines. It is more specific.
ment of N-substituted benzylamines whose aromatic nucleus carries a trifluoromethyl substituent in the meta position.
The invention specifically includes a method for obtaining the compounds of general formula I:
X

~ f - NH ~ / ¦ (I) in which X represents hydrogen, an atom halogen or a trifluoromethyl radical;
Rl represents a lower alkyl radical or a lower cycloalkyl radical;
R2 represents hydrogen or an alkyl radical inferior;
R3 and R4, distinctly or simultaneously represent hydrogen or a lower alkyl radical or form together an alkylene chain having 3 to 6 carbon atoms as well as salts of the compounds of general formula I
with a mineral or organic acid, preferably an acid therapeutically compatible, which consists in cycling by heating a compound of general formula II:

~ 1 - NH - 1l - NH - fH - fH - Hal (Il) in which the definition of the substituents X, R1, R2, R3 and R4 remains unchanged B represents oxygen `~ 106ZZ65 and Hal represents a halogen atom to obtain a compound of general formula I:

F ~ Fz R4 that one can, if desired, salify by adding a mineral or organic acid or split into its isomers optics by combination with an optically active reagent.
The invention also includes a method for obtaining compounds of general formula II which consists of condenses a m. trifluoromethylbenzylamine of general formula 10 III:
X

~ C - NH 2 (III) where X, Rl and R2 are defined as previously with an isocyanate of ~ -halogenoalkyl of formula General IV:
X - CH - CH - N = C = B

in which X is a halogen atom R3 and R4 are defined as above and B is an oxygen atom to produce a urea of general formula II.
Compounds of general formula II can also be obtained by a process which consists of condenses a m. trifluoromethylbenzylamine of general formula III with an aryl haloformate of general formula V:

Ar ~ ~ 6 - Hal (V) o in which Ar is a phenyl radical or a radical phenyle substituted by one or more radicals with character electrophile, to obtain a carbamate of general formula VI:
X

~ f - N ~ - ICl - OAr (VI) where X, Rl, R2 and Ar are defined as previously which is condensed with an aminoalkanol of formula General VII:
2HN - CH - fH - OH (VII) in which R3 and R4 are defined as previously to obtain a ~ -hydroxy alkylated formula General VIII:
X

~ f - NH - CO - NH - fH - fH - OH (VIII) and subjects it to the action of a halogen nation to form a compound of general formula II.
In accordance with the process of the invention, the invention can still be defined by the following execution modes:
- the cyclization of the compound of general formula II
is carried out by heating preferably in an aqueous medium, in -presence or absence of a basic agent capable of fixing the hydracid molecule formed during the cyclic reaction station.
- the basic agent can be a mineral agent such as for example an alkali or alkaline earth metal carbonate, alkali blcarbonate, alkali metal hydroxide, alkaline earth metal, magnesium or aluminum oxide, wn carbonate or magnesium phosphate, a basic salt aluminum.
the basic agent can be an organic agent such as for example a dialkoylamine, a trialcoylamine, dimethyl-aniline, a pyridic base.
- cyclization takes place by heating to a temperature between 50 and 120C, depending on the nature of the solvent and the nature of the molecule to be dehydrogenated. The cyclization preferably takes place around 100.
- aryl haloformate of general formula V
is preferably a chloride or a bromide.
- the aryl radical is preferably a radical phenyle, dinitrophenyle, nitrophenyle, or chloro nitrophenyle.
- the condensation of the aryl halogenoformate with the m. trifluoromethyl benzylamine of the general formula III is performed in the presence of a basic agent such as a trialcoyl-amine, dialkoylaniline, pyridine, collidine, 4-dimethylaminopyridine or dimethylformamide.
the halogenating agent is, for example, chloride thionyl, pentachloride or phosphorus pentabromide, phosphorus oxychloride, N-bromoacetamide.
- the splitting of the compounds of general formula I
is preferably carried out by salification with an acid optically active, for example d-tartaric acid, NN dimethyl tartramic acid, abietic acid, d- acid or l-chrysanthemic, d-glucose l-phosphoric acid, acid l-menthoxy acetic or d-dibenzoyl tartaric acid.
The doubling can also be done on a raw material such as for example a m. trifluoromethyl-benzylamine of general formula III or a ~ -hydroxy alkylated of general formula VIII.
The invention also includes obtaining optically active forms of the compounds of general formula I.
The benzyl carbon atom is substituted by at least three different radicals and therefore asymmetrical. Such a molecule can be split into its optical antipodes.
Also when the oxazolic cycle is substituted by one or more linear or cyclic carbon chains, new centers of symmetry can give birth to double compounds. The resulting optical isomers are also part of the invention.
The invention also relates to a method of preparation of DL N- ~ a-cyclopropyl) (3-trifluoromethyl-phenyl) methy ~ 2-aminooxazoline which consists of condenses DL (3-trifluoromethylphenyl) cyclopropylmethylamine with ~ -chloroethyl isocyanate to form N- (~ -chloro-ethyl) N'- ~ cyclopropyl) (3-trifluoromathylphenyl) methy ~ uree which is cyclized by heating in an aqueous medium to obtain the desired oxazoline.
The invention also relates to a process for the preparation of ration of 2- (a-cyclopropyl) 2- (3'-trifluoromethylphenyl) 2-(oxazolinyl-2 'amino) ethane racemic - or optically active which consists of condensing the 2- (3'-trifluorom ~ thyl-phenyl) 2- (a-cyclopropyl ~ ethylamine racemically or optically active with ~ -chloroethyl isocyanate to obtain ~ -corresponding chloroethyl urea which is cyclized by heating 2- (~ -cyclopropyl) 2- (3'-trifluoromethylphenyl) 2- (oxazolinyl-

2' amino) ethane.
L'invention a encore pour objet l'obtention des isomeres optiques de la N- ~a-cyclopropyl) (3-trifluoromethyl-phenyl) methy ~ 2-aminooxazoline qui consiste en ce que l'on dedouble en ses isomeres optiques la dl (3-trifluoromethyl-phenyl) cyclopropylmethylamine par salification a l'aide de l'acide d-tartrique, opere la synthèse au depart d'un isomere dedouble et obtient finalement l'oxazoline levogyre ou dextro-gyre dedoublee.
L'invention a encore pour objet les composes de formule generale I:
X

~ I--NH~/ I
ainsi que leurs sels d'addition avec un acide mineral ou organique et leurs isomeres optiques chaque fois qu'ils sont obtenus selon le procede de l'invention ou un de ses equivalents chimiques manifestes.
L'invention a plus particulierement pour objet la N- ~ ~-cyclopropyl) (3-trifluoromethylphenyl) methy ~ 2-amino oxazoline sous forme racemique ou optiquement active chaque fois qu'elle est obtenue selon le procede de l'invention ou un de ses equivalents chimiques manifestes.
L'invention se rapporte aussi au 2-(~-cyclopropyl) 2-(3'-trifluoromethylphenyl) 2-(oxazolinyl-2' amino) ethane, sous forme racemique ou optiquement active, chaque fois qu'il est obtenu selon le procede de l'invention ou un de ses equi-valents chimiques manifestes.

L'invention comprend à titre de composes nouveaux, utiles notamment pour l'obtention des composes de formule generale I, les composes de formule generale II:

X

~ C - NH - C - NH - CH - fH - Hal (II) dans laquelle les substituants X, Rl, R2, R3, R4 et B
sont definis comme precedemment et Hal est un atome d'halogene, sous forme racemique ou dedoublée.
- les composes de formule gen~rale VIII:
X

b~ Rl 1 ~ ~ f - NH - CO - NH - CH - fH - OH (VIII) F r R2 R3 R4 dans laquelle la definition des substituants X, R1, R2, R3 et R4 demeure inchangee, sous forme racemique ou dedoublee.
- les benz~lamines de formule generale III:

- NH (III) R

dans laquelle la definition des substituants X, Rl et R2 demeure celle fixee anterieurement, sous forme racemique ou dedoublee.
- les carbamates de formule generale VI:

~ C - NH - C - OAr (Vl~

dans laquelle la definition des substituants X, Rl, R2 et Ar demeure inchangee, sous forme racemique ou d~doublee.
Les composes de formule generale I et leurs sels manifestent des proprietes pharmacologiques interessantes. En particulier ils possedent des proprietes anti-hypertensives tres marquees. Par contre ils ne manifestent de proprietes neurodepressives qu'a des doses tres elevees, bien superieures a celles utilisees pour l'effet anti-hypertensif.
Les composes de formule generale I ainsi que leurs sels trouvent un emploi en therapeutique humaine ou animale, notamment comme agent hypertensif.
Ils se differencient des composes de structure analogue comme ceux decrits dans le brevet americain 3,626,067 par l'extrême reduction des proprietes neurodepressives. Le risque d'apparition de phenomenes de somnolence, de sedation ou de relâchement musculaire se trouve ainsi considerablement reduit.
En vue de l'usage therapeutique, les composes de formule generale I sont employes sous forme de compositions pharmaceutiques, adaptees a l'administration par voie parente-rale, buccale, perlinguale, ou rectale, en association avec un excipient inerte, non-toxique, pharmaceutiquement acceptable.
Les composes pharmaceutiques se presentent sous forme de comprimes nus ou enrobes, de dragees, de solutions ou sus-pension buvables ou injectables,de gelules, de suppositoires, de comprimes sublinguaux, de gels d'emulsions, de sirops ou de gouttes.

La posologie utile Yarie selon l'âge du patient, la gravite de l'indication therapeutique et la voie d'adminis-tration.
Elle peut s'echelonner entre 0.5 mg et 25 mg par pr;se et entre 0.5 mg et 80 mg par jour. La posologie preferae s'echelonne entre 2 mg et 20 mg par prise renouvelee de 1 a 4 fois par jour chez l'homme.
A titre de composes actuellement preferes, on pourra citer plus particulierement:
- la dl 2- ~ 3-trifluorom~thylphenyl~-cyclopropyl-methy ~ aminooxazoline - la d 2- ~ 3-trifluoromethylphenyl)~-cyclopropyl-methy ~ aminooxazoline - la dl 2- ~ 3-trifluoromethyl 4-fluorophenyl)-cyclopropylmethy ~ aminooxazoline - la dl 2- ~ 3,5-ditrifluoromethylphenyl)~-cyclo-propylmethy ~ aminooxazoline - la dl 2- ~ 3-trifluoromethylphenyl) 2-(oxazolinyl-2') amin ~ ethane - la dl 2-(~-cyclopropyl) 2-(oxazolinyl-2') amino-2-(3-trifluoromethylphenyl) ethane et ses isomeres optiques.
Les benzylamines de formule generale III, utilisees comme matieres premieres, sont obtenues d'une maniere generale au depart d'un l-halogeno 3-trifluoromethylbenzene de formule generale:
X

F ~
que l'on fait reagir avec un metal ou un metallo~de en pr~sence de chlorure de cadmium puis avec halogenure d'acide de formule Rl COCl pour former une cetone de formule gen~rale:
X

~C--R
~

puis soumet celle-ci a une reduction, alcoylante ou non, pour former le derive hydroxyle de formule generale:
X

OH
C - R

que l'on transforme en amine correspondante selon les methodes connues par exemple par formation d'un isocyanate, transformation en carbamate puis reduction.
Lorsque R2 est de l'hydrogene les composes de formule generale III peuvent egalement être obtenus par formation d'une oxime au depart d'une cetone de formule generale:
X

\~--CO--R

F C

puis reduction de l'oxime de formule generale:
X

~C--R1 NOH

au moyen d'un metal alcalin dans un alcanol ou d'un hydrure mixte de m~tal alcalin.
Le metal ou le metalloïde utilise pour le premier stade de la pr~paration de la matiere premiere peut etre du magnesium, du zinc, du cadmium, du mercure, du cuivre ou de l'etain.
Le substituant X peut être en n'importe quelle position du cycle benzenique a l'exclusion des positions 1 et
2 'amino) ethane.
Another object of the invention is to obtain optical isomers of N- ~ a-cyclopropyl) (3-trifluoromethyl-phenyl) methy ~ 2-aminooxazoline which consists of split into its optical isomers dl (3-trifluoromethyl-phenyl) cyclopropylmethylamine by salification using d-tartaric acid, synthesizes from an isomer double and finally obtain the levogyre or dextro- oxazoline double gyre.
The invention also relates to the compounds of general formula I:
X

~ I - NH ~ / I
as well as their addition salts with a mineral acid or organic and their optical isomers whenever they are obtained according to the process of the invention or one of its manifest chemical equivalents.
The invention more particularly relates to the N- ~ ~ -cyclopropyl) (3-trifluoromethylphenyl) methy ~ 2-amino oxazoline in racemic or optically active form each once it is obtained according to the process of the invention or a of its manifest chemical equivalents.
The invention also relates to 2- (~ -cyclopropyl) 2- (3'-trifluoromethylphenyl) 2- (oxazolinyl-2 'amino) ethane, in racemic or optically active form, whenever is obtained according to the process of the invention or one of its equi-manifest chemical valents.

The invention comprises, as new compounds, useful in particular for obtaining the compounds of formula general I, the compounds of general formula II:

X

~ C - NH - C - NH - CH - fH - Hal (II) in which the substituents X, R1, R2, R3, R4 and B
are defined as above and Hal is a halogen atom, in racemic form or split.
- the compounds of general formula VIII:
X

b ~ Rl 1 ~ ~ f - NH - CO - NH - CH - fH - OH (VIII) F r R2 R3 R4 in which the definition of the substituents X, R1, R2, R3 and R4 remains unchanged, in racemic form or split.
- the benz ~ lamines of general formula III:

- NH (III) R

in which the definition of the substituents X, Rl and R2 remains the one previously fixed, in racemic form or split.
- the carbamates of general formula VI:

~ C - NH - C - OAr (Vl ~

in which the definition of the substituents X, R1, R2 and Ar remain unchanged, in racemic or dual form.
The compounds of general formula I and their salts show interesting pharmacological properties. In particular they have anti-hypertensive properties very marked. By cons they do not show properties very high doses, much higher to those used for the anti-hypertensive effect.
The compounds of general formula I and their salts find use in human or animal therapy, especially as a hypertensive agent.
They differ from structural compounds analogous like those described in the American patent 3,626,067 by the extreme reduction of neurodepressive properties. The risk of drowsiness, sedation or muscle sagging is found considerably reduced.
For therapeutic use, the compounds of general formula I are used in the form of compositions pharmaceutical, suitable for parenteral administration-oral, buccal, perlingual, or rectal, in combination with a inert, non-toxic, pharmaceutically acceptable excipient.
Pharmaceutical compounds come in the form of naked or coated tablets, dragees, solutions or above oral or injectable board, capsules, suppositories, sublingual tablets, emulsion gels, syrups or drops.

The useful dose Yarie according to the age of the patient, the severity of the therapeutic indication and route of administration tration.
It can range from 0.5 mg to 25 mg per daily and between 0.5 mg and 80 mg per day. The preferred dosage ranges from 2 mg to 20 mg per renewed dose from 1 to 4 times a day in humans.
As currently preferred compounds, to quote more particularly:
- dl 2- ~ 3-trifluorom ~ thylphenyl ~ -cyclopropyl-methy ~ aminooxazoline - d 2- ~ 3-trifluoromethylphenyl) ~ -cyclopropyl-methy ~ aminooxazoline - dl 2- ~ 3-trifluoromethyl 4-fluorophenyl) -cyclopropylmethy ~ aminooxazoline - dl 2- ~ 3,5-ditrifluoromethylphenyl) ~ -cyclo-propylmethy ~ aminooxazoline - dl 2- ~ 3-trifluoromethylphenyl) 2- (oxazolinyl-2 ') amin ~ ethane - dl 2- (~ -cyclopropyl) 2- (oxazolinyl-2 ') amino-2- (3-trifluoromethylphenyl) ethane and its optical isomers.
Benzylamines of general formula III, used as raw materials, are generally obtained from an l-halogeno 3-trifluoromethylbenzene of formula general:
X

F ~
that we react with a metal or a metallo ~
in the presence of cadmium chloride then with acid halide of formula Rl COCl to form a ketone of general formula:
X

~ C - R
~

then subject it to a reduction, alkylating or no, to form the hydroxyl derivative of general formula:
X

OH
C - R

which we transform into a corresponding amine according to known methods for example by the formation of an isocyanate, transformation into carbamate then reduction.
When R2 is hydrogen the compounds of formula III can also be obtained by forming a oxime at the start of a ketone of general formula:
X

--CO - R

FC

then reduction of the general formula oxime:
X

~ C - R1 NOH

using an alkali metal in an alkanol or a mixed hydride of alkali metal.
Metal or metalloid used for the first raw material preparation stage may be magnesium, zinc, cadmium, mercury, copper or tin.
The substituent X can be in any position of the benzenic cycle excluding positions 1 and

3 par rapport à la chafne benzylique.
Dans les definitions fournies ci-dessus le terme alcoyle inferieur designe un radical hydrocarbone ayant de 1 a 6 atomes de carbone comme un methyle, un ethyle, un isopropyle ou un n-hexyle.
Le terme cycloalcoyle inferieur d~signe un radical cyclique sature ayant de 3 a 6 atomes de carbone eventuellement substitue par un ou plusieurs alcoyles inferieur comme un 1,1-dimethylcyclopropyle, un 3,3,5-trimethylcyclohexane ou un cyclopentyle.
Les exemples suivants illustrent l'invention. Ils ne la limitent en aucune façon.
EXEMPLE I
DL N- ~ ~-cyclopropyl) (3-trifluoromethylphenyl) methy ~ 2-aminooxazoline stade a) a-cyclopropyl (3-trifluoromethylphenyl) cetone On prepare le derive magnesien du l-~trifluoromethyl) 3-bromobenzene en solution dans l'ether a partir de 225 9 de l-(trifluoromethyl) 3-bromobenzane de maniare a realiser une concentration de l'ordre de 3 M. On convertit le magnesien en derive cadmie par addition de 0.53 mol de chlorure de cadmium 0. Le melange est ensuite portê au reflux du solvant pendant 60 minutes.
L'ether est distille et remplace au fur et a mesure par un volume double de benzene. On ajoute alors 105 9 de chlorure de l'acide cyclopropane carboxylique goutte a goutte en maintenant la temperature du milieu reactionnel en dessous de 30. Apres achevement de l'addition, on poursuit l'agita-tion pendant une heure puis detruit l'exces de reactif par addition menagee d'acide chlorhydrique. Apres dilution a l'eau, on separe la phase benzenique qu'on lave a l'eau, seche et distille sous vide. On recueille par distillation frac-tionnee 90 g d'~-cyclopropyl (3-trifluoromethylphenyl) cetone soit un rendement de 42%.
Eb = 115-118 n25 _ l 4811 Le spectre IR montre une bande carbonyle.
stade b) ~-cyclopropyl (3-trifluoromethylphenyl) cetoxime On traite 75 9 8 d'a-cyclopropyl (3-trifluoromethyl-phenyl) cetone par 78 g de chlorhydrate d'hydroxylamine dans 280 ml d'un melange a parties egales de pyridine et d'ethanol au reflux pendant 16 heures.
On obtient ainsi 62 9 d'oxime sous forme d'un melange d'isomeres syn et anti. Le produit apres recristallisation du pentane fond a 60-61.
Le spectre infra-rouge montre une bande hydroxyle a 3250 cm 1 et l'absence de bande carbonyle.
stade c) DL-a-cyclopropyl 3-trifluoromethylbenzylamine On dissout 61 g d'a-cyclopropyl (3-trifluoromethyl-phenyl) cêtoxime dans 450 ml d'ether. On ajoute 20 9 d'hydrure de lithium et d'aluminium et on porte au reflux pendant 3 heures. Apres elimination de l'exces de reactif et du solvant, on obtient 41 9 8 d'amine soit un rendement de 65%.

Ebl3 106-110 nD3 - 1,4775 Le produit est purifie par transformation en chlorhydrate F superieur a 260 (sublimation) stade d) chloroethyl) 3-~o~ cyclopropyl) (3-trifluorom~thylbenzyl~7 uree On dissout 4 g 3 d'c~-cyclopropyl m. trifluoromethyl-10 benzylamine dans 8 ml de tetrahydrofuran. On ajoute 2 9 1d'isocyanate de B-chloroethyle dissouts dans 4 ml de tetra-hydrofuran à une temperature ne depassant pas 0. On laisse reposer 4 heures puis distille le solvant sous vide. On recueille ainsi 6.2 9 d'uree soit un rendement de 97~. Apres recristallisation d'un melange de cyclohexane et de benzene on obtient la l-(~-chloroethyl) 3-~ -cyclopropyl) (3-trifluoro-methylbenzyl.~7 uree pure fondant a 91-95.
Le spectre infra-rouge montre une bande -NH- a 3300 cm~
20 stade e) DL N-~-cyclopropyl (3-trifluoromethylphenyl) methy~7 2-amino-oxazoline On met en suspension dans 60 ml d'eau 14 9 de 1-(~-chloroethyl) 3-~T~-cYclopropyl) (3-trifluoromethylbenzyl~7 uree et on porte au reflux pendant 30 minutes. Le produit se dissout progressivement. Apres refroidissement on alcalinise la solution claire par addition progressive de 4 ml d'ammo-niaque. On ~puise la phase aqueuse par l'ether a trois reprises, on separe les solutions etherees que l'on seche et distille a sec sous vide. Le residu sec est repris par l'ether 30 isopropylique. On obtient ainsi 7 9 de produit pur fondant a 84-86 (rendement 60%).

~ - ~

Le spectre IR montre une liaison C=N a 1685 cm 1 EXEMPLE II
dl 2-(a-cyclopropyl) 2-(3'-trifluoromethylphenyl) 2-(oxazolinyl-2' amino) ~thane stade a) methyl ~-cyclopropyl (3-trifluoromethylph~nyl) carbinol On dissout 107 g d'~-cyclopropyl (3-trifluorom~thyl-phenyl) cetone obtenue au stade a) de l'exemple I dans 1000 ml d'ether et on ajoute sous atmosphere inerte 600 ml d'une solu-tion dans l'ether de methyl lithium 1, 65 M a une temperatureinferieure a -10. Apres addition on laisse le melange reac-tionnel revenir a la temperature ordinaire pendant une nuit.
On verse ensuite le melange sur un melange de glace et d'acide chlorhydrique N. La phase aqueuse est epuisee a l'ether. Les solutions organiques sont reunies puis lavees avec une solution de chlorure de sodium jusqu'a ce que les eaux de lavage soient neutres. On seche ensuite sur sulfate de sodium, filtre et ~vapore a sec.
On recueille ainsi 106.5 9 de methyl a-cyc10propyl (3-trifluoromethylphenyl) carbinol soit un rendement de 93%.
Ebl7 123-125 n20 = 1,4765 Analyse C12H13F3 = 230~22 C H %
Calcule 62,61 5,70 Trouve 62,89 5,74 stade b) 2-(3'-trifluoromethylphenyl~ 2-(a-cyclopropyl) ethylamine A une solution de 46 9 de methyl (a-cyclopropyl) (3-trifluoromethylphenyl) carbinol dans lOG ml de tetrahydro-furan on ajoute 8 9 d'hydrure de sodium et on porte le melange au reflux pendant lO heures. On introduit alors sous agitation cette solution dans une solution refroidie de 47 9 de bromure de cyanogene dans 50 ml de tetrahydrofuran. On maintient sous agitation pendant 2 heures a temperature ordinaire puis filtre le bromure de sodium forme et evapore a sec le filtrat. Le residu sec est repris dans lOO ml de methanol et porte au reflux pendant 12 heures. La solution de carbamate ainsi obtenue est évaporee a sec. Le residu est alors additionne de lOO ml d'acide chlorhydrique concentre et chauffe a 60 pendant 8 heures. Apres avoir alcalinise le melange par addition de potasse, on epuise la solution aqueuse a plusieurs reprises de l'ether. On r~unit les phases etherees qu'on lave a l'eau, seche, filtre et evapore a sec. On reprend par une solution saturee de gaz chlorhydrique dans l'ether. Le chlorhydrate de 2-(3'-trifluoromethylphenyl) 2-(-cyclopropyl) ethylamine precip;te. On le separe par filtration et le seche. Apres recristallisation de l'acetonitrile il fond a 180-185.
AnalyseCl2Hl4f3N, ClH = 266,70 C H N Cl%
Calcule54,24 5,69 5,28 13,35 Trouve54,09 5,63 5,39 13,39 stade c) 1-(~-chloroethyl) 3-~-cyclopropyl) methyl (3'-trifluoro-m~thylphenylL/ uree En opêrant selon le mode operatoire de l'exemple I
stade d) on obtient l'uree avec un rendement quantitatif. Le produit est utilise tel quel integralement pour l'etape suivante.
stade d) dl 2-(~-cyclopropyl) 2-(3'-trifluoromethylphenyl) 2-(oxazo-lin 1-2' amino~ ethane y En operant selon le mode operatoire de l'exemple I

stade e) on obtient avec un rendement de 75% la dl 2-(-cyclo-propyl) 2-(3'-trifluoromethylphenyl) 2-(oxazolinyl-2' amino) ethane. Le produit pur fond ~ 112-119.
Analyse C H F N20 ~ 298,30 C H N%
Calcule 60,39 5,75 9,39 Trouve 60,27 6,05 9,35 EXEMPLE III
N- ~-cyclopropyl) (3'-trifluoromethylphenyl) methy 2-aminooxazoline levogyre.
La synthese est effectuee au depart de la (3-tri-fluoromethyl)a-cyclopropyl methylamine dextrogyre selon le mode operatoire de l'exemple I.
La (3-trifluoromethyl)-cyclopropyl methylamine est dedoublee par l'acide d-tartrique en contrôlant en chromato-graphie en phase vapeur la purete de l'isomere optique separe, au moyen du reactif de Mosher.
On obtient ainsi les isomeres suivants:
- (3-trifluoromethylphényl)-cyclopropyl methylamine dextrogyre ~-~ - + 35.6 (c = 1% ethanol) ~-~7 - ~ 130 4 - N-~ra-cyclopropyl) (3-trifluoromethylphenyl) methy~
2-aminooxazoline levogyre - 21 (c = 1% ethanol) ~7 - - 86.4 (c = 1% ethanol) ~06Z265 EXEMPLE IV
N~ cyclopropyl) (3-trifluoromethylphenyl) methy 2-aminooxazoline dextrogyre selon le même mode operatoire qu'a l'exemple III on obtient ~ cyclopropyl (3-trifluoromethylphenyl) methyl-amine levogyre - - 35.8 (c ~ 1% ethanol) 22 o ~ 129.5 (c 1% ethanol) - l'(~-cyclopropyl) (3-trifluoromethylphenyl) methyl 2-aminooxazoline dextrogyre F = 59-65 - + 21.5 (c - 1% ethanol) + 89 (c - 1% ethanol) EXEMPLE V
dl ~-(3'-trifluoromethylph~nyl) 2-(oxazolinyl-2) amin ~ ethane En operant selon le mode operatoire de l'exemple I
au d~part du 2-(3'-trifluoromethylphenyl) 2-amino ethane on obtient la dl 2-(3'-trifluoromethylphenyl) 2-(oxazolinyl-2) amino ethane fondant a 89-94 apres recristallisation de l'ether isopropylique. Le produit est soluble dans l'acide chlorhydrique normal. Apres ~vaporation a sec du solvant on recueille le chlorhydrate de dl ~ -(3i-trifluoromethylph~nyl) 2-(oxazolinyl-2) amin ~ ethane.

Analyse de la base: C12H13F3N202 C H N%
Calcul~ 55,80 5,30 10,82 Trouve 55,69 5,23 10,78 EXEMPLE VI
dl N~ cyclopropyl) (3'-trifluoromethyl 4'-fluoro-phenyl) m~thy ~ 2-aminooxazoline.
En operant selon le mode operatoire de l'exemple I
au depart du l-iodo 3-trifluoromethyl 4-fluorobenzene obtenu au depart de l'o-chloro trifluoromethylbenzene on obtient successivement:
- la (3-trifluoromethyl 4-fluorophenyl)~-cyclopropyl cetone Ebo 6 - 104-107 nD5 - 1,4805 - la ~3-trifluoromethyl 4-fluorophenyl)~-cyclopropyl cetoxime fondant en dessous de 50 (rendement 91%) - la dl (3-trifluoromethyl 4-fluorophenyl) (~-cyclo-propyl) methylamine isolee sous forme de chlorhy~rate fondant au dessus de 250 (decomp.) - la dl 1- ~ 3'-trifluoromethyl 4'-fluorophenyl~ (a-cyclopropyl) methy ~ 3-(~-chloroethyl) uree fondant a 108-111 - la dl N-~a-cycl opropyl) (3-trifluoromethyl 4-fluorophenyl) methy ~ 2-aminooxazoline fondant ~ 81-87 apres recristallisation du pentane.
Analyse C14H14F4N2 302,27 C H N%
Calcule 55,63 4,67 9,27 Trouve 55,83 4,77 9,32 Le compose est soluble dans l'acide chlorhydrique donnant naissance au chlorhydrate.

EXEMPLE YII
dl N- ~ 3,5-ditrifluoromethylphenyl) (a-cyclopropyl methyl ~ 2-aminooxazoline.
En operant selon le mode operatoire de l'exemple I
au depart du l-iodo 3,5-(ditrifluoromethyl) benzane obtenu selon le proc~de decrit dans le J. of Am. Chem. Soc. 75 (1953) 4967-4969 on obtient successivement:
- la (3,5-ditrifluoromethyl)a-cyclopropyl cetone Ebl = 79-81 nD22 = 1,444 - la (3,5-ditrif'luoromethylphenyl)a-cyclopropyl cetoxime Ebo 7 ~ 82-85 - la dl (3,5-ditrifluoromethylphenyl) (a-cyclopropyl) methylamine Ebl2 = 98-102 - son chlorhydrate fond au dessus de 250 - la N-(~-chloroethyl) N'- ~ a-cyclopropyl) (3,5-ditr;fluoromethylphenyl) methy ~ uree fondant a 128-132 - la dl ~ 3,5-ditrifluoromethylphenyl) (a-cyclo-propyl) m~thy ~ 2-aminooxazoline fondant a 133-138 apres recristallisation de l'ether de petrole.
Analyse C15H14F6N20 352,27 C H N~
Calcule 51,14 4,01 7,95 Trouve 51,54 4,3 7,95 Le compose est soluble dans l'acide chlorhydrique normal.
EXEMPLE VIII
Etude pharmacologique des compos~s de formule generale I:
- determination de la toxicit~ aigu~
La dose lethale moyenne a ~te determin~e sur des lots de souris Rockland pesant 20-22 g par injection intra-peritoneale de doses croissantes des produits a essayer. La dose lethale moyenne est determinee graphiquement après avoir denombre les morts apras 8 jours d'observation. Les resultats suivants ont ete obtenus:
- compose de l'exemple I DL50 env. 100 mg/kg - compose de l'exemple II DL50 env. 40 mg/kg - compose de l'exemple III DL50 ~50 mg/kg - compose de l'exemple IV DL50 >50 mg/kg - compose de l'exemple V DL50 entre 50 et 100 mg/kg - compos~ de l'exemple VI DL50 entre 50 et 100 mg/kg - compose de l'exemple VII DL50 entre 100 et 200 mg/kg - recherche d'une activite neurodepressive Chez la souris la premiere dose attestant d'une action sur le systeme nerveux central est d~ja subtoxique et se situe au voisinage de 25 mg/kg par voie intraperitoneale.
On constate une legere baisse de la motricite et une perte du tonus musculaire. Une dose de 50 mg/kg n'aggrave pas le tableau de sedation.
Les produits de l'invention ont ete compares avec un analogue structurel non trifluoromethyle. Celui-ci possade une DL50 de 30 mg/kg. La premiere dose neurosedative chez la souris est de 1 mg/kg par voie intraperitoneale et de 500 y/kg IP chez le rat.
Au contraire le composê de l'exemple II a pour effet aussi bien chez la souris que chez le rat d'augmenter la motricite, le tonus muscualire et l'excitabilit~. Il ne paraft donc pas y avoir a ces doses d'effet neurodepresseur.
- determination de l'effet anti-hypertensif L'activite anti-hypertensive a ete mise en evidence pour les composes de l'invention sur le chien rendu hypertensif par nephrosclerose.

Le produit injecte par voie intraveineuse ~ des doses comprises entre 0.05 et 0.5 mg/kg provoque une baisse de la pression arterielle superieure a 10 mm Hg et d'une duree superieure a 1 heure. En outre on constate une diminution de la frequence cardiaque de 10 a 20% selon les doses injectees.
3 compared to the benzyl chain.
In the definitions provided above the term lower alkyl denotes a hydrocarbon radical having from 1 to 6 carbon atoms such as methyl, ethyl, isopropyl or an n-hexyl.
The term lower cycloalkyl signifies a radical saturated cyclic having 3 to 6 carbon atoms possibly substituted by one or more lower alkyls such as 1,1-dimethylcyclopropyle, a 3,3,5-trimethylcyclohexane or a cyclopentyle.
The following examples illustrate the invention. They do not limit it in any way.
EXAMPLE I
DL N- ~ ~ -cyclopropyl) (3-trifluoromethylphenyl) methy ~ 2-aminooxazoline stage a) a-cyclopropyl (3-trifluoromethylphenyl) ketone We prepare the magnesium derivative of l- ~ trifluoromethyl) 3-bromobenzene in solution in ether from 225 9 of l- (trifluoromethyl) 3-bromobenzane to carry out a concentration of the order of 3 M. We convert the magnesian into cadmium derivative by adding 0.53 mol of cadmium chloride 0. The mixture is then brought to reflux of the solvent for 60 minutes.
The ether is distilled and replaces as and when with a double volume of benzene. We then add 105 9 of cyclopropane carboxylic acid chloride drop by drop keeping the temperature of the reaction medium below of 30. After the addition is completed, the agitation is continued.
tion for one hour and then destroys the excess reagent by household addition of hydrochloric acid. After dilution at water, we separate the benzenic phase which we wash with water, dry and distills under vacuum. Frac-tionnee 90 g of ~ -cyclopropyl (3-trifluoromethylphenyl) ketone or a yield of 42%.
Eb = 115-118 n25 _ l 4811 The IR spectrum shows a carbonyl band.
stage b) ~ -cyclopropyl (3-trifluoromethylphenyl) cetoxime 75 9 8 of a-cyclopropyl (3-trifluoromethyl-phenyl) ketone per 78 g of hydroxylamine hydrochloride in 280 ml of an equal parts mixture of pyridine and ethanol at reflux for 16 hours.
62 9 of oxime are thus obtained in the form of a mixture of syn and anti isomers. The product after recrystallization of the pentane melts at 60-61.
The infrared spectrum shows a hydroxyl band a 3250 cm 1 and the absence of carbonyl band.
stage c) DL-a-cyclopropyl 3-trifluoromethylbenzylamine 61 g of a-cyclopropyl (3-trifluoromethyl-phenyl) cetoxime in 450 ml of ether. 20% of hydride are added of lithium and aluminum and the mixture is brought to reflux for 3 hours. After elimination of excess reagent and solvent, 41 9 8 of amine are obtained, ie a yield of 65%.

Ebl3 106-110 nD3 - 1.4775 The product is purified by transformation into hydrochloride F greater than 260 (sublimation) stage d) chloroethyl) 3- ~ o ~ cyclopropyl) (3-trifluorom ~ thylbenzyl ~ 7 urea 4 g 3 of c ~ -cyclopropyl m are dissolved. trifluoromethyl-10 benzylamine in 8 ml of tetrahydrofuran. 2 9 1 of B-chloroethyl isocyanate dissolved in 4 ml of tetra- is added.
hydrofuran at a temperature not exceeding 0. We leave stand 4 hours then distill the solvent in vacuo. We thus collects 6.2 9 of duration which is a yield of 97 ~. After recrystallization of a mixture of cyclohexane and benzene on obtains l- (~ -chloroethyl) 3- ~ -cyclopropyl) (3-trifluoro-methylbenzyl. ~ 7 pure urea melting at 91-95.
The infrared spectrum shows a band -NH- a 3300 cm ~
20 stage e) DL N- ~ -cyclopropyl (3-trifluoromethylphenyl) methy ~ 7 2-amino-oxazoline Is suspended in 60 ml of water 14 9 of 1- (~ -chloroethyl) 3- ~ T ~ -cYclopropyl) (3-trifluoromethylbenzyl ~ 7 uree and the mixture is brought to reflux for 30 minutes. The product is gradually dissolves. After cooling we alkalize the clear solution by progressive addition of 4 ml of ammonia niac. We draw the aqueous phase with ether three times, we separate the ethereal solutions that we dry and dry distilled under vacuum. The dry residue is taken up by ether Isopropyl. 7 9 of pure product thus obtained are obtained.
84-86 (yield 60%).

~ - ~

The IR spectrum shows a bond C = N at 1685 cm 1 EXAMPLE II
dl 2- (a-cyclopropyl) 2- (3'-trifluoromethylphenyl) 2-(oxazolinyl-2 'amino) ~ thane stage a) methyl ~ -cyclopropyl (3-trifluoromethylph ~ nyl) carbinol 107 g of ~ -cyclopropyl (3-trifluorom ~ thyl-) are dissolved phenyl) ketone obtained in stage a) of Example I in 1000 ml of ether and 600 ml of a solution are added under an inert atmosphere tion in methyl lithium ether 1, 65 M at a temperature below -10. After addition, the mixture is left to react.
return to room temperature overnight.
The mixture is then poured over a mixture of ice and acid hydrochloric N. The aqueous phase is exhausted with ether. The organic solutions are combined and then washed with a solution sodium chloride until the wash water is neutral. Then dried over sodium sulfate, filtered and ~ dry vapor.
106.5 9 of methyl a-cyc10propyl are thus collected.
(3-trifluoromethylphenyl) carbinol, ie a yield of 93%.
Ebl7 123-125 n20 = 1.4765 Analysis C12H13F3 = 230 ~ 22 CH%
Calculate 62.61 5.70 Find 62.89 5.74 stage b) 2- (3'-trifluoromethylphenyl ~ 2- (a-cyclopropyl) ethylamine To a 46 9 solution of methyl (a-cyclopropyl) (3-trifluoromethylphenyl) carbinol in lOG ml of tetrahydro-furan we add 8 9 of sodium hydride and we wear the mixture at reflux for 10 hours. Then introduced with stirring this solution in a cooled solution of 47 9 bromide of cyanogen in 50 ml of tetrahydrofuran. We keep under stirring for 2 hours at ordinary temperature then filter sodium bromide forms and evaporates the filtrate to dryness. The dry residue is taken up in 100 ml of methanol and brought to reflux for 12 hours. The carbamate solution as well obtained is evaporated to dryness. The residue is then added with 100 ml of concentrated hydrochloric acid and heated to 60 for 8 hours. After alkalizing the mixture by adding potash, the aqueous solution is exhausted several times from ether. We unite the ethereal phases which we wash with water, dries, filters and evaporates to dryness. We resume with a solution saturated with hydrochloric gas in ether. Hydrochloride 2- (3'-trifluoromethylphenyl) 2 - (- cyclopropyl) ethylamine precip; te. It is separated by filtration and dried. After recrystallization from acetonitrile it melts at 180-185.
Analysis Cl2Hl4f3N, ClH = 266.70 CHN Cl%
Calculate 54.24 5.69 5.28 13.35 Found 54.09 5.63 5.39 13.39 stage c) 1- (~ -chloroethyl) 3- ~ -cyclopropyl) methyl (3'-trifluoro-m ~ thylphenylL / uree By operating according to the operating mode of example I
stage d) the urea is obtained with a quantitative yield. The product is used as is integrally for the step next.
stage d) dl 2- (~ -cyclopropyl) 2- (3'-trifluoromethylphenyl) 2- (oxazo-linen 1-2 'amino ~ ethane y By operating according to the operating mode of example I

stage e) dl 2 - (- cyclo- is obtained with a yield of 75%
propyl) 2- (3'-trifluoromethylphenyl) 2- (oxazolinyl-2 'amino) ethane. The pure product melts ~ 112-119.
Analysis CHF N20 ~ 298.30 CHN%
Calculate 60.39 5.75 9.39 Find 60.27 6.05 9.35 EXAMPLE III
N- ~ -cyclopropyl) (3'-trifluoromethylphenyl) methy Levogyre 2-aminooxazoline.
The synthesis is carried out at the start of the (3-tri-fluoromethyl) a-cyclopropyl methylamine dextrorotatory according to the mode example I.
(3-trifluoromethyl) -cyclopropyl methylamine is split by d-tartaric acid by checking in chromato-graphs in vapor phase the purity of the separate optical isomer, using Mosher's reagent.
The following isomers are thus obtained:
- (3-trifluoromethylphenyl) -cyclopropyl methylamine dextrorotary ~ - ~ - + 35.6 (c = 1% ethanol) ~ - ~ 7 - ~ 130 4 - N- ~ ra-cyclopropyl) (3-trifluoromethylphenyl) methy ~
Levogyre 2-aminooxazoline - 21 (c = 1% ethanol) ~ 7 - - 86.4 (c = 1% ethanol) ~ 06Z265 EXAMPLE IV
N ~ cyclopropyl) (3-trifluoromethylphenyl) methy 2-aminooxazoline dextrorotatory according to the same operating mode as in Example III, obtains ~ cyclopropyl (3-trifluoromethylphenyl) methyl-levogyre amine - - 35.8 (c ~ 1% ethanol) 22 o ~ 129.5 (c 1% ethanol) - (~ -cyclopropyl) (3-trifluoromethylphenyl) methyl 2-aminooxazoline dextrorotatory F = 59-65 - + 21.5 (c - 1% ethanol) + 89 (c - 1% ethanol) EXAMPLE V
dl ~ - (3'-trifluoromethylph ~ nyl) 2- (oxazolinyl-2) amin ~ ethane By operating according to the operating mode of example I
from 2- (3'-trifluoromethylphenyl) 2-amino ethane on obtains dl 2- (3'-trifluoromethylphenyl) 2- (oxazolinyl-2) amino ethane melting at 89-94 after recrystallization of isopropyl ether. The product is soluble in acid normal hydrochloric. After ~ dry vaporization of the solvent on collects dl ~ - (3i-trifluoromethylph ~ nyl) hydrochloride 2- (oxazolinyl-2) amin ~ ethane.

Analysis of the base: C12H13F3N202 CHN%
Calculation ~ 55.80 5.30 10.82 Found 55.69 5.23 10.78 EXAMPLE VI
dl N ~ cyclopropyl) (3'-trifluoromethyl 4'-fluoro-phenyl) m ~ thy ~ 2-aminooxazoline.
By operating according to the operating mode of example I
from the l-iodo 3-trifluoromethyl 4-fluorobenzene obtained from o-chloro trifluoromethylbenzene we get successively:
- (3-trifluoromethyl 4-fluorophenyl) ~ -cyclopropyl cetone Ebo 6 - 104-107 nD5 - 1.4805 - ~ 3-trifluoromethyl 4-fluorophenyl) ~ -cyclopropyl cetoxime melting below 50 (91% yield) - dl (3-trifluoromethyl 4-fluorophenyl) (~ -cyclo-propyl) methylamine isolated in the form of chlorhy ~ melting spleen above 250 (decomp.) - dl 1- ~ 3'-trifluoromethyl 4'-fluorophenyl ~ (a-cyclopropyl) methy ~ 3- (~ -chloroethyl) uree fondant at 108-111 - dl N- ~ a-cycl opropyl) (3-trifluoromethyl 4-fluorophenyl) methy ~ 2-aminooxazoline fondant ~ 81-87 after recrystallization of pentane.
Analysis C14H14F4N2 302.27 CHN%
Calculate 55.63 4.67 9.27 Found 55.83 4.77 9.32 The compound is soluble in hydrochloric acid giving rise to the hydrochloride.

EXAMPLE YII
dl N- ~ 3,5-ditrifluoromethylphenyl) (a-cyclopropyl methyl ~ 2-aminooxazoline.
By operating according to the operating mode of example I
from l-iodo 3,5- (ditrifluoromethyl) benzane obtained according to the process described in the J. of Am. Chem. Soc. 75 (1953) 4967-4969 we obtain successively:
- (3,5-ditrifluoromethyl) a-cyclopropyl cetone Ebl = 79-81 nD22 = 1.444 - (3,5-ditrif'luoromethylphenyl) a-cyclopropyl cetoxime Ebo 7 ~ 82-85 - dl (3,5-ditrifluoromethylphenyl) (a-cyclopropyl) methylamine Ebl2 = 98-102 - its hydrochloride melts above from 250 - N- (~ -chloroethyl) N'- ~ a-cyclopropyl) (3,5-ditr; fluoromethylphenyl) methy ~ uree fondant a 128-132 - dl ~ 3,5-ditrifluoromethylphenyl) (a-cyclo-propyl) m ~ thy ~ 2-aminooxazoline melting at 133-138 after recrystallization of petroleum ether.
Analysis C15H14F6N20 352.27 CHN ~
Calculate 51.14 4.01 7.95 Find 51.54 4.3 7.95 The compound is soluble in hydrochloric acid normal.
EXAMPLE VIII
Pharmacological study of the compounds of formula general I:
- determination of toxicity ~ acute ~
The average lethal dose has been determined on batches of Rockland mice weighing 20-22 g by intravenous injection increasing doses of the products to be tested. The average lethal dose is determined graphically after count the dead after 8 days of observation. The results The following were obtained:
- consists of example I DL50 approx. 100 mg / kg - consists of example II LD50 approx. 40 mg / kg - consists of Example III LD50 ~ 50 mg / kg - consists of example IV LD50> 50 mg / kg - consists of example V LD50 between 50 and 100 mg / kg - compound ~ of Example VI LD50 between 50 and 100 mg / kg - consists of Example VII LD50 between 100 and 200 mg / kg - search for neurodepressive activity In mice the first dose attesting to a action on the central nervous system is already subtoxic and is around 25 mg / kg intraperitoneally.
There is a slight drop in motor skills and a loss of Muscle tone. A dose of 50 mg / kg does not worsen the sedation chart.
The products of the invention were compared with a non-trifluoromethyl structural analogue. This one has an LD50 of 30 mg / kg. The first neurosedative dose in mouse is 1 mg / kg intraperitoneally and 500 y / kg PI in rats.
On the contrary, the compound of Example II has the effect in both mice and rats to increase the motor skills, muscle tone and excitability. It does not appear therefore not have these doses of neurodepressant effect.
- determination of the anti-hypertensive effect Anti-hypertensive activity has been highlighted for the compounds of the invention on the hypertensive dog by nephrosclerose.

The product injects intravenously ~ doses between 0.05 and 0.5 mg / kg causes a drop in the blood pressure greater than 10 mm Hg and lasting greater than 1 hour. In addition, there is a decrease in heart rate from 10 to 20% depending on the doses injected.

Claims (8)

Les réalisations de l'invention, au sujet desquelles un droit exclusif de propriété ou de privilège est revendiqué, sont définies comme il suit: The embodiments of the invention, about which an exclusive right of property or privilege is claimed, are defined as follows: 1. Un procédé d'obtention des méta trifluorométhyl benzylamines N-substituées répondant à la formule générale I:

(I) dans laquelle X représente de l'hydrogène, un atome d'halogène ou un radical trifluorométhyle;
R1 représente un radical alcoyle inférieur ou un radical cycloalcoyle inférieur;
R2 représente de l'hydrogène ou un radical alcoyle inférieur;
R3 et R4 distinctement ou simultanément, représentent de l'hydrogène ou un radical alcoyle inférieur ou forment ensemble une chaîne alcoylène ayant de 3 à 6 atomes de carbone, ainsi que des sels des composés de formule générale I
avec un acide minéral ou organique, sous forme racémique ou optiquement active, caractérisé en ce qu'on cyclise par chauffage un composé de formule générale II:

(II) dans laquelle la définition des substituants X, R1, R2, R3 et R4 demeure inchangée B représente de l'oxygène et Hal représente un atome d'halogène pour obtenir un composé de formule générale I:

que l'on peut, si désiré, salifier par addition d'un acide minéral ou organique thérapeutiquement tolérable ou dédoubler en ses isomères optiques par combinaison avec un réactif optiquement actif.
1. A process for obtaining meta trifluoromethyl N-substituted benzylamines corresponding to general formula I:

(I) in which X represents hydrogen, an atom halogen or a trifluoromethyl radical;
R1 represents a lower alkyl radical or a lower cycloalkyl radical;
R2 represents hydrogen or an alkyl radical inferior;
R3 and R4 distinctly or simultaneously, represent hydrogen or a lower alkyl radical or form together an alkylene chain having 3 to 6 carbon atoms, as well as salts of the compounds of general formula I
with a mineral or organic acid, in racemic or optically active form, characterized in that a compound of general formula II:

(II) in which the definition of the substituents X, R1, R2, R3 and R4 remains unchanged B represents oxygen and Hal represents a halogen atom to obtain a compound of general formula I:

which can, if desired, be salified by adding a therapeutically tolerable mineral or organic acid or split into its optical isomers by combination with a optically active reagent.
2. Un procédé selon la revendication 1 dans lequel les composés de formule générale II sont obtenus en condensant une m. trifluorométhylbenzylamine de formule générale III:

(III) dans laquelle X, R1 et R2 sont définis comme précédemment avec un isocyanate d'.omega.-halogénoalcoyle de formule générale IV:
(IV) dans laquelle X est un atome d'halogène R3 et R4 sont définis comme précédemment et B est un atome d'oxygène pour produire une urée de formule générale II.
2. A method according to claim 1 wherein the compounds of general formula II are obtained by condensing a m. trifluoromethylbenzylamine of general formula III:

(III) where X, R1 and R2 are defined as previously with an omega.-haloalkyl isocyanate of formula general IV:
(IV) in which X is a halogen atom R3 and R4 are defined as above and B is an oxygen atom to produce a urea of general formula II.
3. Un procédé selon la revendication 1 dans lequel les composés de formule générale II sont obtenus en condensant une m. trifluorométhylbenzylamine de formule générale III avec un haloformiate d'aryle de formule générale V:
Ar - O - ? - Hal (V) dans laquelle Ar est un radical phényle ou un radical phényle substitué par un ou plusieurs radicaux à caractère électrophile, pour obtenir un carbamate de formule générale VI:

(VI) dans laquelle X, R1, R2 et Ar sont définis comme précédemment que l'on condense avec un aminoalcanol de formule générale VII:
(VII) dans laquelle R3 et R4 sont définis comme précédemment pour obtenir une .beta.-hydroxy alcoylurée de formule générale VIII:

(VIII) et soumet celle-ci à l'action d'un agent d'halogé-nation pour former un composé de formule générale II.
3. A method according to claim 1 in which the compounds of general formula II are obtained by condensing a m. trifluoromethylbenzylamine general formula III with an aryl haloformate of formula general V:
Ar - O -? - Hal (V) in which Ar is a phenyl radical or a radical phenyl substituted by one or more radicals of a character electrophile, to obtain a carbamate of general formula VI:

(VI) where X, R1, R2 and Ar are defined as previously which is condensed with an aminoalkanol of formula general VII:
(VII) in which R3 and R4 are defined as previously to obtain an alkylated .beta.-hydroxy of formula general VIII:

(VIII) and subjects it to the action of a halogenating agent.
nation to form a compound of general formula II.
4. Un procédé selon la revendication 1 ou la reven-dication 2 pour obtenir la N-[(.alpha.-cyclopropyl) (3-trifluoro-méthylphényl) méthyl] 2-aminooxazoline qui consiste en ce que l'on condense la (3-trifluorométhylphényl) cyclopropylméthyl-amine racémique ou optiquement active avec l'isocyanate de .beta.-chloroéthyle pour obtenir la .beta.-chloroéthyl urée correspondante sous forme racémique ou optiquement active et cyclise celle-ci par chauffage en milieu aqueux pour former l'oxazoline désirée. 4. A method according to claim 1 or the res-dication 2 to obtain N - [(. alpha.-cyclopropyl) (3-trifluoro-methylphenyl) methyl] 2-aminooxazoline which consists of the (3-trifluoromethylphenyl) cyclopropylmethyl- is condensed racemic or optically active amine with .beta isocyanate.
chloroethyl to obtain the corresponding .beta.-chloroethyl urea in racemic or optically active form and cyclizes it by heating in an aqueous medium to form the desired oxazoline.
5. Un procédé selon la revendication 1 ou la reven-dication 2 pour obtenir le 2-(.alpha.-cyclopropyl) 2-(3'-trifluoro-méthylphényl) 2-oxazolinyl-2' amino) éthane racémique ou optiquement actif caractérisé en ce que l'on condense la 2-(3'-trifluorométhylphényl) 2-(.alpha.-cyclopropyl) éthylamine racémique ou optiquement active avec l'isocyanate de .beta.-chloro-éthyle pour former la .beta.-chloroéthyl urée correspondante que l'on cyclise par chauffage en milieu aqueux, en 2-(.alpha.-cyclo-propyl) 2-(3'-trifluorométhylphényl) 2-(oxazolinyl-2' amino) éthane racémique ou optiquement actif. 5. A process according to claim 1 or the resale dication 2 to obtain 2 - (. alpha.-cyclopropyl) 2- (3'-trifluoro-methylphenyl) 2-oxazolinyl-2 'amino) ethane racemic or optically active characterized in that the 2-(3'-trifluoromethylphenyl) 2 - (. Alpha.-cyclopropyl) ethylamine racemic or optically active with .beta.-chloro- isocyanate ethyl to form the corresponding .beta.-chloroethyl urea that cyclized by heating in an aqueous medium, in 2 - (. alpha.-cyclo-propyl) 2- (3'-trifluoromethylphenyl) 2- (oxazolinyl-2 'amino) racemic or optically active ethane. 6. Les m. trifluorométhylbenzylamines N-substituées répondant à la formule générale I:

(I) dans laquelle X représente de l'hydrogène, un atome d'halogène ou un radical trifluorométhyle;
R1 représente un radical alcoyle inférieur ou un radical cycloalcoyle inférieur;
R2 représente de l'hydrogène ou un radical alcoyle inférieur;

R3 et R4 distinctement ou simultanément, représentent de l'hydrogène ou un radical alcoyle inférieur ou forment ensemble une chaîne alcoylène ayant de 3 à 6 atomes de carbone ainsi que leurs sels d'addition avec un acide minéral ou organique thérapeutiquement tolérable, chaque fois qu'ils sont obtenus par le procédé de la revendication 1 ou un de ses équivalents chimiques manifestes.
6. The m. N-substituted trifluoromethylbenzylamines corresponding to general formula I:

(I) in which X represents hydrogen, an atom halogen or a trifluoromethyl radical;
R1 represents a lower alkyl radical or a lower cycloalkyl radical;
R2 represents hydrogen or an alkyl radical inferior;

R3 and R4 distinctly or simultaneously, represent hydrogen or a lower alkyl radical or form together an alkylene chain having 3 to 6 carbon atoms as well as their addition salts with a mineral acid or therapeutically tolerable organic, each time they are obtained by the process of the claim 1 or one of its obvious chemical equivalents.
7. La N- [(.alpha.-cyclopropyl) (3-trifluorométhylphényl) méthyl] 2-aminooxazoline racémique ou optiquement active chaque fois qu'elle est obtenue selon le procédé de la revendication 4 ou un de ses équivalents chimiques manifestes. 7. N- [(.alpha.-cyclopropyl) (3-trifluoromethylphenyl) racemic or optically active methyl] 2-aminooxazoline each once it is obtained according to the method of claim 4 or one of its obvious chemical equivalents. 8. Le 2-(.alpha.-cyclopropyl) 2-(3'-trifluorométhylphényl) 2-(oxazolinyl-2' amino) éthane racémique ou optiquement actif chaque fois qu'il est obtenu selon le procédé de la revendica-tion 5 ou un de ses équivalents chimiques manifestes. 8. 2 - (. Alpha.-cyclopropyl) 2- (3'-trifluoromethylphenyl) 2- (oxazolinyl-2 'amino) ethane racemic or optically active each time it is obtained according to the process of the claim tion 5 or one of its manifest chemical equivalents.
CA229,350A 1974-06-20 1975-06-13 Process of preparation of new benzylamines Expired CA1062265A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA332,309A CA1078869A (en) 1974-06-20 1979-07-20 Process for the preparation of novel benzylamines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2739274A GB1475513A (en) 1974-06-20 1974-06-20 Benzylamine derivatives process for science union et cie benzylamine derivatives process for their production and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
CA1062265A true CA1062265A (en) 1979-09-11

Family

ID=10258850

Family Applications (1)

Application Number Title Priority Date Filing Date
CA229,350A Expired CA1062265A (en) 1974-06-20 1975-06-13 Process of preparation of new benzylamines

Country Status (18)

Country Link
JP (1) JPS5231341B2 (en)
AT (1) AT342046B (en)
AU (1) AU497501B2 (en)
BE (1) BE830442A (en)
CA (1) CA1062265A (en)
CH (1) CH597206A5 (en)
DE (1) DE2526965A1 (en)
DK (1) DK136313B (en)
ES (1) ES438757A1 (en)
FI (1) FI751825A (en)
FR (1) FR2275207A1 (en)
GB (1) GB1475513A (en)
HU (1) HU173390B (en)
IE (1) IE41382B1 (en)
NL (1) NL7507422A (en)
SE (2) SE7507018L (en)
SU (1) SU578880A3 (en)
ZA (1) ZA753943B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358890A1 (en) * 1976-05-24 1978-02-17 Science Union & Cie NEW ARYL TRIFLUOROETHYLAMINES, THEIR METHODS OF OBTAINING AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING
JPS53105752U (en) * 1977-01-31 1978-08-25
JPS5495252A (en) * 1978-01-11 1979-07-27 Oki Electric Ind Co Ltd Thermal printer
FR2444673A1 (en) * 1978-12-20 1980-07-18 Science Union & Cie NOVEL TRIFLUOROETHYLAMINES, PROCESSES FOR OBTAINING SAME AND THEIR USE AS MEDICAMENTS
JPS57136755U (en) * 1981-02-20 1982-08-26
AUPP020297A0 (en) * 1997-11-05 1997-11-27 University Of Melbourne, The A novel receptor, and compounds which bind thereto

Also Published As

Publication number Publication date
AT342046B (en) 1978-03-10
DK274375A (en) 1975-12-21
FR2275207A1 (en) 1976-01-16
SU578880A3 (en) 1977-10-30
IE41382B1 (en) 1979-12-19
DK136313C (en) 1978-02-20
CH597206A5 (en) 1978-03-31
ZA753943B (en) 1976-06-30
IE41382L (en) 1975-12-20
SE7507018L (en) 1975-12-22
AU8224675A (en) 1976-12-23
JPS5116662A (en) 1976-02-10
HU173390B (en) 1979-04-28
GB1475513A (en) 1977-06-01
AU497501B2 (en) 1978-12-14
JPS5231341B2 (en) 1977-08-13
FR2275207B1 (en) 1979-08-10
NL7507422A (en) 1975-12-23
SE7900681L (en) 1979-01-25
DK136313B (en) 1977-09-26
ATA471675A (en) 1977-07-15
ES438757A1 (en) 1977-03-16
BE830442A (en) 1975-12-19
DE2526965A1 (en) 1976-01-02
FI751825A (en) 1975-12-21

Similar Documents

Publication Publication Date Title
EP0447285B1 (en) Naphthalene derivatives, procedure for their preparation and pharmaceutical compositions containing them
EP0099789B1 (en) 3-aminoquinuclidin derivatives, process for their preparation and their use as therapeutical agents
EP0082088B1 (en) Derivatives of amino acids and their therapeutic use
CA2542647C (en) Derivatives of n-heterocyclylmethylbenzamides, prepartion method thereof and application of same in therapeutics
CA1088939A (en) Indole derivatives used as drugs
EP0042781B1 (en) 1-(4 quinolyl), 2- or 3- (2- or 3- piperidyl or pyrrolidinyl) ethanone or propanone, process for their preparation and their use as medicaments
WO2005118547A1 (en) Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
CA2119662C (en) New nitrogen bicyclic derivatives, their preparation process and pharmaceutical compositions comtaining them
CA1062265A (en) Process of preparation of new benzylamines
CH649994A5 (en) 4H-1,2,4-TRIAZOLE DERIVATIVES, METHODS OF PREPARATION AND COMPOSITIONS CONTAINING THEM.
CH625214A5 (en)
CH630606A5 (en) Phenylamidine derivatives useful especially in therapeutics
CA1139763A (en) Process for preparing novel aryltrifluoroethanols
CA1042905A (en) Preparation of new bisubstituted azabicycloalkans_
US4567198A (en) Ethanethioates and mercaptoamides and use thereof as analgesic and enkephalinase inhibitory compounds
JPH0156071B2 (en)
FR2610323A1 (en) ABSOLUTE CONFIGURATION ENANTIOMERS OF AMINO-3 QUINUCLIDINE AMIDE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
CA1078869A (en) Process for the preparation of novel benzylamines
CA1052788A (en) Process for the preparation of novel n-substituted acetamides and derivatives thereof
FR2846654A1 (en) New dihydro-4(1H)-pyridinone derivatives are useful in the treatment of cognitive disorders, neurodegenerative diseases and pain
HU176277B (en) Process for producing cycloalkyl-amine derivatives
CH658786A5 (en) DRUGS THAT CONTAIN ALPHA- (N-PYRROLYL) -ACIDS OR THEIR SALTS OR ESTERS.
EP0534856B1 (en) Oxime ethers of thienocyclopentanones, their preparation and pharmaceutical compositions containing them
US3903165A (en) Ethynylaryl amines and processes for their preparation
CH392508A (en) Process for preparing esters of 3-phenyl-3-pyrrolidinols